JPMorgan Resumes Pfizer (PFE) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Jefferies Reiterates Buy on Pfizer (PFE) Post Allergen Collapse, PT Trimmed to $39
April 7, 2016 8:23 AM EDTJefferies analyst, Jeffrey Holford, performed a SOTP valuation on fizer (NYSE: PFE) after the Allergan deal was terminated and believes shares have 18% upside by 2017 as the decision on the split has been reinstated to 2016. He also sees the potential for major M&A to give more critical mass to GIP in particular. Using a SOTP analysis, he derives a value of... More
Pfizer (PFE) Announces Termination of Merger Agreement with Allergan (AGN)
April 6, 2016 6:45 AM EDTPfizer Inc. (NYSE: PFE) announced that the merger agreement between Pfizer and Allergan plc (NYSE: AGN) has been terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an Adverse Tax Law Change... More
